J
John Cunningham
Researcher at University College London
Publications - 32
Citations - 5431
John Cunningham is an academic researcher from University College London. The author has contributed to research in topics: Secondary hyperparathyroidism & Kidney disease. The author has an hindex of 18, co-authored 32 publications receiving 4908 citations.
Papers
More filters
Journal ArticleDOI
Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
Sharon M. Moe,Tilman B. Drüeke,John Cunningham,Wayne K. Goodman,Kevin J. Martin,Klaus Olgaard,Susan M. Ott,Stuart M. Sprague,Norbert Lameire,Garabed Eknoyan +9 more
TL;DR: It is recommended that the term renal osteodystrophy be used exclusively to define alterations in bone morphology associated with CKD, and the term CKD-Mineral and Bone Disorder (CKD-MBD) be used to describe a broader clinical syndrome that develops as a systemic disorder of mineral and bone metabolism due to CKD.
Journal ArticleDOI
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Geoffrey A. Block,Kevin J. Martin,Angel L.M. de Francisco,Stewart A. Turner,Morrell M. Avram,Michael Suranyi,Gavril Hercz,John Cunningham,Ali K. Abu-Alfa,Piergiorgio Messa,Daniel W. Coyne,Francesco Locatelli,Raphael M. Cohen,Pieter Evenepoel,Sharon M. Moe,Albert Fournier,Johann Braun,Laura C. McCary,Valter J. Zani,Kurt Olson,Tilman B. Drüeke,William G. Goodman +21 more
TL;DR: Cinacalcet lowers parathyroid hormone levels and improves calcium-phosphorus homeostasis in patients receiving hemodialysis who have uncontrolled secondary hyperparathyroidism.
Journal ArticleDOI
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
TL;DR: Combining results from 4 clinical trials, randomization to cinacalcet led to significant reductions in the risk of parathyroidectomy, fracture, and cardiovascular hospitalization, along with improvements in self-reported physical function and diminished pain.
Journal ArticleDOI
Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options
TL;DR: Treatment of secondary hyperparathyroidism in CKD patients should include a combination of dietary phosphorus restriction, phosphate binders, vitamin D sterols, and calcimimetics, and future strategies may focus on the stimulation of apoptotic activity of hyperplastic parathyroid cells.
Journal ArticleDOI
Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl
Sharon M. Moe,Glenn M. Chertow,Jack W. Coburn,L. Darryl Quarles,William G. Goodman,Geoffrey A. Block,Tilman B. Drüeke,John Cunningham,Donald J. Sherrard,Laura C. McCary,Kurt Olson,Stewart A. Turner,Kevin J. Martin +12 more
TL;DR: In subjects on dialysis with secondary HPT, cinacalcet facilitates achievement of the K/DOQI-recommended targets for PTH, calcium, phosphorus, and Ca x P.